PIK3CA and cancer: Dactolisib (NVP-BEZ235) is an orally bioavailable, reversible, ATP-competitive dual PI3K and mTORC1/2 inhibitor, which has been widely used in preclinical studies on various cancers including GBM, breast, colorectal and lung cancers [89–92].